All In Biotech

Drug Trial Radar · NCT03312634

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Nov 30, 2017

Primary completion

Jan 24, 2020

Study completion Sep 7, 2022

Sponsor

Lead sponsor
Clementia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • PalovaroteneDrug

    Palovarotene was taken orally once daily at approximately the same time each day following a meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized New Heterotopic Ossification (HO)Time frame: Baseline (within one month of screening/Day 1) and up to 24 months

Locations

16 sites in 11 countries. Site status is shown where the registry gives one.

  • University of California San Francisco, Division of Endocrinology and Metabolism

    San Francisco, California

  • Mayo Clinic

    Rochester, Minnesota

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pennsylvania, Internal Medicine

    Philadelphia, Pennsylvania

  • Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190

    Buenos Aires, Argentina

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Queensland University of Technology

    Woolloongabba, Queensland, Australia

  • Hospital Israelita Albert Einstein

    São Paulo, São Paulo, Brazil

  • Hospital for Sick Children, 555 University Avenue

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France

  • Istituto Giannina Gaslini

    Genoa, Liguria, Italy

  • The University of Tokyo Hospital

    Tokyo, Bunkyo-ku, Japan

  • Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica

    Valencia, Avinguda de Fernando Abril Martorell, Nº 106, Spain

  • Norrlands Universitetssjukhus

    Umeå, Sweden

  • Royal National Orthopaedic Hospital, Brockely Hill

    Stanmore, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.